Search Results for: Pharmaceutical

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults.

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults.

Coronavirus Literature
Publication date: Jul 28, 2026 Background/Objectives: Waning immunity after primary COVID-19 vaccination supports evaluation of additional doses. HXP-GPOVac is an egg-based, inactivated Newcastle disease virus (NDV)-vectored vaccine expressing a prefusion-stabilized ... Read more